Tocagen Inc (NASDAQ:TOCA) has received an average broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a hold rating and one has issued a strong buy rating on the company.

Brokers have set a 1 year consensus target price of $23.67 for the company and are anticipating that the company will post ($0.52) EPS for the current quarter, according to Zacks. Zacks has also assigned Tocagen an industry rank of 166 out of 265 based on the ratings given to related companies.

Several research firms recently commented on TOCA. Leerink Swann began coverage on Tocagen in a report on Monday, May 8th. They issued a “market perform” rating and a $19.00 price objective for the company. Stifel Nicolaus started coverage on Tocagen in a research note on Monday, May 8th. They set a “buy” rating and a $24.00 price target for the company. Finally, Evercore ISI restated an “outperform” rating and set a $28.00 price target on shares of Tocagen in a research note on Tuesday, May 9th.

ILLEGAL ACTIVITY NOTICE: “Zacks: Brokerages Set $23.67 Target Price for Tocagen Inc (TOCA)” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was stolen and republished in violation of U.S. & international trademark & copyright law. The original version of this news story can be read at

Tocagen (TOCA) traded up 0.13% during trading on Monday, reaching $14.97. 140,406 shares of the company traded hands. The company’s 50-day moving average price is $15.85 and its 200 day moving average price is $15.37. The firm’s market capitalization is $296.51 million. Tocagen has a 52 week low of $10.25 and a 52 week high of $17.95.

Tocagen (NASDAQ:TOCA) last released its quarterly earnings data on Tuesday, May 23rd. The company reported ($4.11) EPS for the quarter, missing the consensus estimate of ($2.70) by $1.41. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.01 million. On average, equities research analysts expect that Tocagen will post ($2.79) EPS for the current year.

In other news, Director Paul Schimmel purchased 10,000 shares of the business’s stock in a transaction on Wednesday, April 19th. The stock was acquired at an average cost of $10.00 per share, for a total transaction of $100,000.00. Following the purchase, the director now directly owns 23,464 shares in the company, valued at approximately $234,640. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Mark G. Foletta purchased 5,000 shares of the business’s stock in a transaction on Wednesday, April 19th. The shares were purchased at an average price of $10.00 per share, with a total value of $50,000.00. Following the completion of the purchase, the chief financial officer now owns 5,000 shares in the company, valued at $50,000. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 42,500 shares of company stock valued at $425,000.

About Tocagen

Tocagen Inc (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to selectively deliver therapeutic genes into the deoxyribonucleic acid (DNA) of cancer cells.

Get a free copy of the Zacks research report on Tocagen (TOCA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Tocagen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tocagen Inc and related companies with's FREE daily email newsletter.